A5054228821- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Lung Cancer Diagnosis and Treatment
- Virus-based gene therapy research
- Cancer Genomics and Diagnostics
- Histone Deacetylase Inhibitors Research
- HER2/EGFR in Cancer Research
- Immune cells in cancer
- Epigenetics and DNA Methylation
- PI3K/AKT/mTOR signaling in cancer
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Cancer therapeutics and mechanisms
- Brain Metastases and Treatment
- Intracranial Aneurysms: Treatment and Complications
- Vascular Malformations Diagnosis and Treatment
- Meningioma and schwannoma management
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
Moffitt Cancer Center
2017-2025
The University of Texas MD Anderson Cancer Center
2025
University of South Florida
2017-2023
University of Maryland, Baltimore
2011-2015
University of Maryland Medical Center
2015
Radiation Oncology Associates
2012
Human epidermal growth factor receptor 2 (HER2)-targeted therapies have not been approved for patients with non-small-cell lung cancer (NSCLC). The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody-drug conjugate, in
Abstract Purpose: Histone deacetylase inhibitors (HDACi) enhance tumor immunogenicity through several mechanisms and may improve response to immune checkpoint (ICIs). In a phase I/Ib trial, we tested the oral HDACi vorinostat combined with programmed cell death protein 1 inhibitor pembrolizumab in advanced/metastatic non–small lung cancer. Patients Methods: received intravenous (200 mg every 3 weeks) plus or 400 mg/day). Primary endpoint was safety/tolerability. Secondary endpoints included...
9504 Background: T-DXd is an antibody-drug conjugate composed of anti-HER2 antibody, cleavable tetrapeptide-based linker, and topoisomerase I inhibitor payload. In a phase trial, patients (pts) with HER2-mutated NSCLC who received had confirmed objective response rate (ORR) 72.7% (8/11) (Tsurutani et al, WCLC 2018). DESTINY-Lung01 (NCT03505710) ongoing, multicenter, II study in pts non-squamous overexpressing HER2 or containing HER2-activating mutation. We report data for the cohort...
For patients with advanced non-small-cell lung cancer (NSCLC), dual immune checkpoint blockade (ICB) CTLA4 inhibitors and PD-1 or PD-L1 (hereafter, PD-(L)1 inhibitors) is associated higher rates of anti-tumour activity immune-related toxicities, when compared treatment alone. However, there are currently no validated biomarkers to identify which will benefit from ICB1,2. Here we show that NSCLC who have mutations in the STK11 and/or KEAP1 tumour suppressor genes derived clinical ICB...
PURPOSE Preclinical studies demonstrated that dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial (VEGF) pathways delay the emergence resistance to EGFR tyrosine kinase inhibitors (TKIs), in trials with first-generation TKIs, combination VEGF pathway prolonged progression-free survival (PFS). METHODS The RAMOSE trial (ClinicalTrials.gov identifier: NCT03909334 , HCRN LUN-18-335) is a randomized, open-label multicenter phase II study comparing osimertinib...
The object of this study was to assess outcomes in patients with arteriovenous malformations (AVMs) treated by Gamma Knife stereotactic radiosurgery (SRS); lesions were stratified size, symptomatology, and Spetzler-Martin (S-M) grade.The authors performed a retrospective analysis 102 for an AVM single-dose or staged-dose SRS between 1993 2004. Lesions grouped S-M grade, as hemorrhagic nonhemorrhagic, small (< 3 cm) large (≥ cm). Outcomes included death, morbidity (new neurological deficit,...
Abstract Oncolytic virus therapies induce the direct killing of tumor cells and activation conventional dendritic (cDC); however, cDC has not been optimized with current therapies. We evaluated adenoviral delivery engineered membrane-stable CD40L (MEM40) IFNβ to locally activate cDCs in mouse models. Combined MEM40 expression induced highest coupled increased lymph node migration, systemic antitumor CD8+ T-cell responses, regression established tumors a cDC1-dependent manner. + combined...
// Andreas Saltos 1 , Farah Khalil 2 Michelle Smith Jiannong Li 3 Michael Schell Scott J. Antonia and Jhanelle E. Gray Department of Thoracic Oncology, H. Lee Moffitt Cancer Center Research Institute, Tampa, Florida, USA Anatomic Pathology, Biostatistics/Bioinformatics, Correspondence to: Gray, email: jhanelle.gray@moffitt.org Keywords: lung cancer; tumor pathology; glycoprotein; MUC1; non-small cell cancer Received: May 01, 2018 Accepted: October 06, Published: November 02, ABSTRACT Mucin...
Abstract Study Objectives: A hallmark of tumor infiltrating lymphocytes (TIL) in melanoma is the potential for a complete response (CR) which can last decades. This long-lived effect attributed to persistence memory T cells. However, clinical efficacy metastatic non-small cell lung cancer (mNSCLC) has not previously been reported. We launched phase I trial with objective evaluate safety and mNSCLC after evidence progression on nivolumab. Methodology: Full eligibility criteria described...
Background: The optimal treatment sequencing for patients with metastatic epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) remains a subject of debate. In the United States, osimertinib is preferred EGFR tyrosine kinase inhibitor (TKI) in first-line setting. However, small retrospective studies suggest that alternative TKI strategies may produce similar outcomes. This study aimed to compare outcomes NSCLC harboring an exon 19 deletion or 21 L858R mutation...
<p class="western"><span style="font-size: medium;">Background: The incidence of injuries sustained by cell phone users other than drivers and pedestrians is not well characterized. </span></p><p medium;">Methods: National Electronic Injury Surveillance (NEISS) database was searched to identify involving use in all settings. study period January 2000 December 2012. medium;">Results: We identified 515 records ED visits related use. 48% occurred the home...